The Brighton, UK-based biotech, Destiny Pharma listed on the UK junior stock market AIM with an IPO worth £15.3m ($19.8m) in gross proceeds on Sept. 4, and announced on the same day a development and commercialization deal for its investigational products covering China, underlining the significant progress being made by the company.
Destiny Pharma Floats on UK AIM And Completes China Deal
An agreement covering the development and commercialization of its products in China underlines the potential of now-publicly listed Destiny Pharma’s investigational antibacterial to evade the emergence of resistance.
